UBS Group’s Hepion Pharmaceuticals HEPA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-1
| Closed | – | – | 10497 |
|
|
2025
Q1 | $0 | Sell |
1
-280
| -100% | -$2.73K | ﹤0.01% | 10430 |
|
|
2024
Q4 | $6.59K | Buy |
+281
| New | +$8.77K | ﹤0.01% | 8545 |
|
|
2024
Q3 | – | Sell |
-1
| Closed | -$40 | – | 9414 |
|
|
2024
Q2 | $71 | Sell |
1
-3
| -75% | -$221 | ﹤0.01% | 9205 |
|
|
2024
Q1 | $455 | Buy |
+4
| New | +$460 | ﹤0.01% | 8548 |
|
|
2023
Q4 | – | Hold |
0
| – | – | – | 9147 |
|
|
2023
Q3 | – | Sell |
-53
| Closed | -$19.8K | – | 9215 |
|
|
2023
Q2 | $28K | Buy |
53
+39
| +279% | +$23.9K | ﹤0.01% | 6745 |
|
|
2023
Q1 | $10.9K | Buy |
+14
| New | +$10.3K | ﹤0.01% | 7542 |
|
|
2022
Q4 | – | Sell |
-11
| Closed | -$5K | – | 10877 |
|
|
2022
Q3 | $5K | Buy |
+11
| New | +$6.72K | ﹤0.01% | 9196 |
|
|
2022
Q2 | – | Sell |
-2
| Closed | -$2K | – | 10568 |
|
|
2022
Q1 | $2K | Sell |
2
-8
| -80% | -$8.84K | ﹤0.01% | 9633 |
|
|
2021
Q4 | $12K | Sell |
10
-38
| -79% | -$52K | ﹤0.01% | 8557 |
|
|
2021
Q3 | $74K | Buy |
48
+25
| +109% | +$40K | ﹤0.01% | 6044 |
|
|
2021
Q2 | $46K | Sell |
23
-45
| -66% | -$82.3K | ﹤0.01% | 6509 |
|
|
2021
Q1 | $125K | Buy |
68
+67
| +6,700% | +$147K | ﹤0.01% | 5788 |
|
|
2020
Q4 | $1K | Sell |
1
-1
| -50% | -$2.59K | ﹤0.01% | 8218 |
|
|
2020
Q3 | $5K | Buy |
+2
| New | +$7.18K | ﹤0.01% | 7302 |
|
|
2020
Q1 | – | Sell |
-3
| Closed | -$18K | – | 8130 |
|
|
2019
Q4 | $18K | Sell |
3
-1
| -25% | -$3.87K | ﹤0.01% | 6939 |
|
|
2019
Q3 | $9K | Buy |
+4
| New | +$11.6K | ﹤0.01% | 7214 |
|
|
2019
Q2 | – | Hold |
0
| – | – | – | 7977 |
|
|
2019
Q1 | – | Hold |
0
| – | – | – | 7541 |
|
|
2018
Q4 | – | Hold |
0
| – | – | – | 7279 |
|
|
2018
Q3 | – | Hold |
0
| – | – | – | 7487 |
|
|
2018
Q2 | – | Hold |
0
| – | – | – | 8088 |
|
|
2018
Q1 | – | Hold |
0
| – | – | – | 7532 |
|
|
2017
Q4 | – | Hold |
0
| – | – | – | 7466 |
|
|
2017
Q3 | – | Hold |
0
| – | – | – | 6524 |
|
|
2017
Q2 | – | Hold |
0
| – | – | – | 6412 |
|
|
2016
Q3 | – | Hold |
0
| – | -$5K | – | 7775 |
|
|
2016
Q2 | – | Hold |
0
| – | – | – | 7118 |
|
|
2016
Q1 | – | Hold |
0
| – | -$10K | – | 7849 |
|
|
2015
Q4 | – | Hold |
0
| – | – | – | 7276 |
|
|
2015
Q3 | – | Hold |
0
| – | – | – | 8080 |
|
|
2015
Q2 | – | Hold |
0
| – | – | – | 8639 |
|
|
2015
Q1 | – | Hold |
0
| – | – | – | 8445 |
|
Other funds holding HEPA
UBS Group's HEPA Position: Q2 2025 in Review
UBS Group sold out of Hepion Pharmaceuticals (HEPA) in Q2 2025, closing a stake of 1 share.
UBS Group first reported a position in HEPA in Q3 2019 and held it in 16 quarters. The position peaked at $125K in Q1 2021. 4 funds tracked by Wall St. Rank hold HEPA as of Q2 2025.
- UBS Group reported no remaining Hepion Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
- UBS Group sold 1 Hepion Pharmaceuticals share in Q2 2025.
- UBS Group first reported a position in Hepion Pharmaceuticals in Q3 2019 and held it in 16 quarters.
- UBS Group's Hepion Pharmaceuticals position peaked at $125K in Q1 2021.
- 4 funds tracked by Wall St. Rank held Hepion Pharmaceuticals as of Q2 2025.
Based on UBS Group's 13F filing for Q2 2025, filed 14 Aug 2025.